Streetbeat News

Regulatory

NRSN

NeuroSense Therapeutics has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange. This development is crucial for maintaining investor confidence and access to capital markets.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:07 pm

NRSN

NeuroSense Therapeutics has been granted a U.S. patent for its novel PrimeC formulation, extending its intellectual property protection through 2042. This strengthens the company's IP position by adding four additional years to its coverage.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:06 pm

CVX

DRLL

HES

XLE

XOM

Chevron's merger with Hess is likely to receive FTC approval soon, potentially accelerating the $53 billion deal. Despite arbitration claims from Exxon Mobil and CNOOC regarding Hess' Guyana joint venture, the merger could proceed earlier than expected. Chevron and Hess shares are trading higher on this news.

Portfolio Pulse from Lekha Gupta

September 24, 2024 | 1:05 pm

AYRWF

CURLF

TCNNF

Hispanic voters in Florida, who make up 22% of the electorate, are increasingly supporting cannabis legalization, with 60% backing Amendment 3. This trend could significantly impact the cannabis market in Florida, potentially leading to a 400% growth if the amendment passes. Key players like Trulieve, Curaleaf, and Ayr Wellness could benefit from this expansion.

Portfolio Pulse from Nicolás Jose Rodriguez

September 24, 2024 | 12:59 pm

LLY

Eli Lilly's Alzheimer's treatment, Donanemab (Kisunla), has been approved in Japan, marking its second largest market. The approval is based on positive Phase 3 trial results showing significant slowing of disease progression. This approval could impact Eli Lilly's market presence and stock performance.

Portfolio Pulse from Vandana Singh

September 24, 2024 | 12:50 pm

GOOG

Alphabet has been targeted by an unsolicited mini-tender offer from Tutanota to buy up to 350,000 shares of its Class C stock at $180 per share. Alphabet cautions stockholders against the offer, which represents less than 0.01% of the outstanding shares.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:48 pm

ENLV

Enlivex has received a recommendation from the Data and Safety Monitoring Board (DSMB) to proceed with the Phase II stage of its Allocetra trial for moderate to severe knee osteoarthritis, following a successful Phase I safety review.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:37 pm

VTAK

Catheter Precision has received a Chinese patent for its LockeT device, which is used in cardiac procedures. This development could enhance the company's market position and product offerings.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:35 pm

SAVA

Cassava Sciences announced that an independent Data and Safety Monitoring Board (DSMB) has completed an interim safety review of its oral Simufilam in ongoing Phase 3 trials. The DSMB recommended that the trials continue as planned without modifications. Final clinical safety data will be available at the end of the Phase 3 program.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:32 pm

AUPH

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced the approval of its drug LUPKYNIS (voclosporin) by the Japanese Ministry of Health for treating lupus nephritis. This approval follows a successful clinical program and collaboration with Otsuka Pharmaceutical.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:32 pm